B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

J Cancer Res Clin Oncol. 2009 Oct;135(10):1351-8. doi: 10.1007/s00432-009-0576-6. Epub 2009 Mar 27.

Abstract

Purpose: Surveillance of urothelial carcinoma of the urinary bladder (UBC) patients with respect to tumour recurrence and invasiveness is crucial for therapy and prognosis. Therefore, evaluation of non-invasive methods to monitor tumour progression is of high clinical interest. The study was aimed at investigating urinary concentrations of tenascin-C splicing domains for their value as tumour surveillance markers.

Methods: Urinary concentration of B and C domain containing tenascin-C (Tn-C) was analysed by ELISA technology in 104 UBC patients, 11 patients with cystitis and 15 healthy donors as control. The investigation was supplemented by Tn-C immunohistochemistry and Western blotting.

Results: A statistically significant increase in urinary concentrations of both Tn-C B and C domain with tumour progression could be evidenced. A concordant tumour-associated enhanced protein deposition in the carcinoma stroma could be demonstrated by immunohistochemistry in invasive UBC. Western blotting reveals proteolytic fragmentation of urinary Tn-C.

Conclusions: In summary, detection of Tn-C splicing domains in urine is suggested as a marker for the surveillance of UBC recurrence and invasiveness.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / urine*
  • Blotting, Western
  • Carcinoma, Transitional Cell / secondary
  • Carcinoma, Transitional Cell / urine*
  • Case-Control Studies
  • Cystitis / urine
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunoenzyme Techniques
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / urine*
  • Neoplasm Staging
  • Prognosis
  • Protein Structure, Tertiary
  • Tenascin / urine*
  • Urinary Bladder / metabolism
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / urine*

Substances

  • Biomarkers, Tumor
  • Tenascin